In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18f]hx4 and [18f]fdg-pet/ct imaging

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6389-6397

  Zegers, Catharina M L ^a,f   Van Elmpt, Wouter ^a   Reymen, Bart ^a   Even, Aniek J G ^a   Troost, Esther G C ^a   Öllers, Michel C ^a   Hoebers, Frank J P ^a   Houben, Ruud ^a   Eriksson, Jonas ^b   Windhorst, Albert D ^b   Mottaghy, Felix M ^c,d   De Ruysscher, Dirk ^a,e   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MAASTRO CLINIC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLORTANIDAZOLE F 18; FLUORODEOXYGLUCOSE F 18; HX4 COMPOUND; IMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; HYPOXIA; IN VIVO STUDY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; METABOLIC PARAMETERS; NON SMALL CELL LUNG CANCER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; RADIOLOGICAL PARAMETERS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; AGED; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; IMAGE PROCESSING; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE PROCESSING, COMPUTER-ASSISTED; IMIDAZOLES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 84919683000     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1524     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
3. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
4. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-speci fic PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8.
5. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012;18: 2108-14.
6. Zegers CM, van Elmpt W, Wierts R, Reymen B, Sharifi H, Ollers MC, et al. Hypoxia imaging with [(18)F]HX4 PET in NSCLC patients: defi ning optimal imaging parameters. Radiother Oncol 2013;109: 58-64.
7. Bollineni VR, Kerner GS, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, et al. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med 2013;54:1175-80.
8. Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011;108:14620-5.
9. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010;37:1663-8.
10. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. (1)(8)F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO. Nucl Med Commun 2012;33:1096-102.
11. Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386-92.
12. Abramyuk A, Tokalov S, Zophel K, Koch A, Szluha Lazanyi K, Gillham C, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 2009;91:399-404.
13. Spijkerman J, Fontanarosa D, Das M, van Elmpt W. Validation of nonrigid registration in pretreatment and follow-up PET/CT scans for quanti fication of tumor residue in lung cancer patients. J Appl Clin Med Phys 2014;15:4847.
14. Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2013;10:27-40.
15. Aerts HJ, Lambin P, Ruysscher DD. FDG for dose painting: a rational choice. Radiother Oncol 2010;97:163-4.
16. Lambin P, Petit SF, Aerts HJ, van Elmpt WJ, Oberije CJ, StarmansMH, et al. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol 2010;96:145-52.
17. Pereira KM, Chaves FN, Viana TS, Carvalho FS, Costa FW, Alves AP, et al. Oxygen metabolism in oral cancer: HIF and GLUTs (review). Oncol Lett 2013;6:311-6.
18. van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II doseescalation trial in non-small cell lung cancer. Radiother Oncol 2012;104:67-71.
19. Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun 2010;31:1016-24.
20. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification ofFDGwhole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320-33.
21. Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18Ffluoromisonidazole and 18F-FDG PET. J Nucl Med 2006;47:1921-6.
22. Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with (1)(8)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)(8)F-fluoro-thymidine (FLT), and hypoxia with (1)(8) fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non -small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 2011;98:109-16.
23. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapyrelevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007;7:113.
24. Cistaro A, Quartuccio N, Mojtahedi A, Fania P, Filosso PL,Campenni A, et al. Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification. Radiol Oncol 2013;47:219-23.
25. Tanaka H, Hayashi S, Hoshi H. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy. Asia Pac J Clin Oncol 2013.
26. Satoh Y, Onishi H, Nambu A, Araki T. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Radiology 2014;270:275-81.
27. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60.
28. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and metaanalysis. Radiother Oncol 2011;100:22-32.
29. Arrieta O, Blake M, de la Mata-Moya MD, Corona F, Turcott J, Orta D, et al. Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer. Radiother Oncol 2014;111:311-5.
30. Saggar JK, Tannock IF. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer 2014;134:2726-34.
31. Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948-53.
32. Moller DS, Khalil AA, Knap MM, Muren LP, Hoffmann L. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non -small cell lung cancer patients. Acta Oncol 2011;50:883-8.
33. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
34. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-83.
35. Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-54.
36. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, GrahamMM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
37. Petit SF, Dekker AL, Seigneuric R, Murrer L, van Riel NA, Nordsmark M, et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol 2009;54:2179-96.
38. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
39. Due AK, Vogelius IR, Aznar MC, BentzenSM, Berthelsen AK, Korreman SS, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 2014;111:360-5.
40. Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol 2013;108: 511-6.
41. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8.
42. Bosmans G, van Baardwijk A, Dekker A, Ollers M, Boersma L, Minken A, et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non -small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2006;66:748-53.
43. Yu ZH, Lin SH, Balter P, Zhang L, Dong L. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers. Radiother Oncol 2012;104:33-8.
44. Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol 2012;105:36-40.
45. Aerts HJ, Bosmans G, van Baardwijk AA, Dekker AL, Oellers MC, Lambin P, et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys 2008;71:1402-7.
46. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol imaging 2013;40:186-97.
47. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54:201-7.